New Market - January 27, 2015
Novo to Market Saxenda in U.S.
Novo Nordisk plans to put 500 U.S. sales reps, or about one-sixth of that country’s sales force, to work marketing its newly-approved weight-loss drug Saxenda, a reformulated version of diabetes drug Victoza (liraglutide). In an interview with the Financial Times, Novo Chief Science Officer Mads Krogsgaard Thomsen said his company is looking to generate at […]
Drug Development Pharma - January 12, 2015
FDA OKs Novo Weight-Loss Drug
Two months after its own deadline, the U.S. Food and Drug Administration (FDA) issued approval for Novo Nordisk’s first weight-loss therapy. Approved was Novo’s Saxenda for use in managing weight in conjunction with diet and exercise. Saxenda is a higher dose of the diabetes treatment liraglutide. The drug is indicated for patients who qualify as […]
